ezetimibe
not tagged
[]
 not the case for primary prevention. subgroup analysis in primary shows 33% reduction in cv outcomes which clearly beat eztemibe and psk-9-i. not to mention in secondary prevention ezetimibe+ nexletol ( nexletzet) will provide (7+9 % in cv outcomes which is on par with psk-9i.